2 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Approved WMORecruiting
Primary Objective:To compare the fate of the struts in front of the side-branch using optical coherence tomography after treatment with 1. COMBO or 2. XIENCE stent using single stent strategy with side-branch fenestration in the treatment of (a)…